Spotlight On... Google-backed Zephyr Health helping device and drug companies hit sales targets with Big Data; JustRight gets $11.2M to market tiny sealer, stapler; Toshiba imaging has as many as 10 suitors; and more...

San Francisco's Zephyr Health is attracting lots of attention thanks to its software for ranking doctors' influence on others, a valuable metric when deciding whom the sales team should visit, or whom to invite to a conference. And it has branched into the device world. Along with Big Pharma players Amgen ($AMGN) and GlaxoSmithKline ($GSK), the company counts Stryker ($SYK) as one of its customers. "You're desperate for data to make those key (sales and marketing) decisions," Zephyr CEO Lance Scott told Bloomberg. "But while there's lots of data out there, it's really challenging to bring it together." The company has about $34 million in VC funding. Backers include GV (formerly Google Ventures), which boasts a life science portfolio worth $800 million. More

@FierceMedDev: Next 'blow up' for Theranos? The company's latest legal hire: NYT. Article | Follow @FierceMedDev

@EmilyWFierce: Come for a story about stem cell therapy in felines. Stay for a pic of Bob the cat. More from FierceAnimalHealth | Follow @EmilyWFierce

> JustRight Surgical nabs $4.2 million in a Series B with an additional $7 million in debt to back marketing of its 3mm JustRight Sealer and its JustRight 5mm Stapler, which it said are 5 to 9 times smaller than prior iterations. More

> Toshiba reportedly has at least 10 potential buyers involved in bidding to buy its imaging business including Sony, Mitsui & Co. and Hitachi. Article

> Implantable continuous glucose monitor company Senseonics ($SENH) has partnered with Diasend to enable clinical review of data from the former's Eversense CGM. More

Biotech News

@FierceBiotech: FierceBiotech Radio on Gilead's wide-open future, biotech's long winter and Sanofi's ongoing makeover. More/Subscribe | Follow @FierceBiotech

@JohnCFierce: ICYMI: Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging. Article | Follow @JohnCFierce

> J&J goes all in with ViaCyte, hands over BetaLogics assets in hunt for diabetes cure. Story

> Twist Bio's hard-charging CEO hit by claims she stole Agilent's trade secrets. Report

> InflaRx starts preparation for PhIIb septic organ dysfunction trial after clearing safety study. Article

Pharma News

@FiercePharma: Stem cell therapy developed to treat dental disease in cats could also help people. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Teva is adding 20 jobs at UK plant, but only after cutting 80 as it looks for different skills. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa. Report from FiercePharmaMarketing | Follow @CarlyHFierce

> Media-magnet hearing on Capitol Hill gets underway, with Valeant, Turing under spotlight. News

> Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters. Story

> Patent losses looming, AZ fights back with Brilinta, diabetes and China. Article

CRO News

> Onyx Scientific expands again as GMP demand grows. Article

> Catalent invests more in Asia, beefing up a Singapore supply outpost. More

> Fox Foundation backs Evotec's Parkinson's project. Report

> French CRO Novasep bulks up its manufacturing services in the U.S. Story

> BioClinica launches new research offering for marketed meds. Article

Pharma Manufacturing News

> Pakistani man charged with bringing counterfeit drugs into U.S. Report

> Ipca's small-scale API producer in U.K. expanding. Story

> Sanofi commits to developing Zika vax while other big players will evaluate. Item

> Valeant's Bausch + Lomb recalls more than 1M bottles of eye med. More

> Sanofi says job cuts in France should not involve plant closures. Article

Pharma Asia News

> Japan's Daiichi Sankyo joins clinical trial data request system. News

> Pfizer's busy Q4 in emerging markets a prelude for the big show. More

> BeiGene comes in at top end of range in Nasdaq IPO, raising $158.4M. Report

> Asia included in Zika virus warning zone as drugmakers ponder vaccines. Story

> GSK's CEO says it's 'difficult to understand how company is doing.' Article

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.